Yangzhou Prince Pharmaceutical Technology Co., Ltd. is located in Yangzhou City, Jiangsu Province. Established in 2003, the company specializes in the research, development, and production of novel pharmaceutical intermediates, specialty chemicals, and distinctive generic drugs. It holds controlling or participating shares in factories located in Yangzhou (Jiangsu), Anqing (Anhui), and Alxa (Inner Mongolia). In the urban area of Yangzhou, the company has established a business center and a research and development center.

The company excels in various types of reactions, including etherification, amination, chlorination, esterification, cyclization, hydrogenation, and Grignard reactions. Over the past decade, it has developed more than 400 catalog products, including over 40 key pharmaceutical intermediates. These intermediates are involved in areas such as anticancer, cardiovascular, digestive system, and psychiatric diseases, covering key intermediates for active pharmaceutical ingredients like quetiapine, fluvoxamine, erlotinib, gefitinib, sunitinib, lapatinib, rabeprazole, and lafutidine. For many years, the company has been supplying high-quality pharmaceutical intermediates to numerous globally renowned pharmaceutical enterprises.

In 2011, the company was recognized as a "High-Tech Enterprise." It adheres to a path of technological innovation and holds more than 10 authorized invention patents.

The company insists on using international standard management systems to advance all aspects of its operations. It has established an ISO9001:2000 quality management system, an ISO14001:2004 environmental management system, and an OHS18001:1999 occupational health and safety management system. Over the years, it has passed on-site audits conducted by more than 20 international and domestic pharmaceutical companies.